Betahistine mesylate
CAS : 54856-23-4
Ref. 3D-FB170146
10g | Arrêté | ||
25g | Arrêté | ||
50g | Arrêté | ||
100g | Arrêté | ||
250g | Arrêté |
Informations sur le produit
- 2-Pyridineethanamine, N-methyl-, dimethanesulfonate
- 2-Pyridineethanamine, N-methyl-, methanesulfonate (1:2)
- Betahistine Mesilate
- Betahistine Mesylate
- Betahistine dimesylate
- Bethahistine methanesulfonate
- Merislon
- N-methyl-2-(pyridin-2-yl)ethanamine methanesulfonate (1:2)
Betahistine mesylate is a pharmaceutical preparation that is used for the treatment of vertigo, Meniere's disease, and Ménière's disease. It has been shown to reduce the frequency of attacks in patients with Ménière's disease. Betahistine mesylate is also used to treat symptoms of Ménière's disease such as nausea and vomiting. This drug has been shown to have a statistically significant effect on reducing the severity of vertigo in patients with Ménière's disease, but not in those with Meniere's disease. The mechanism by which betahistine mesylate exerts its therapeutic effects may involve an effect on fatty acid metabolism or glucose injection into cells.